About Bivalirudin Dosing

This clinical guide provides information related to the Bivalirudin dose calculator. Bivalirudin is a direct thrombin inhibitor used as an anticoagulant in patients undergoing percutaneous coronary intervention (PCI) and in those with, or at risk for, heparin-induced thrombocytopenia (HIT) or HIT with thrombosis syndrome (HITTS).

Proper bivalirudin administration requires precise, weight-based calculations and adjustments for renal function to balance antithrombotic efficacy with the risk of bleeding. This information is intended for educational purposes and should not replace clinical judgment or official prescribing information.

Calculator Outputs Explained

After entering the required patient data, the calculator provides the following key outputs for safe administration:

• Bolus Dose (mg): The total initial dose in milligrams, administered as an intravenous push.
• Bolus Volume (mL): The volume of the prepared IV solution to administer for the bolus, based on the specified bag concentration.
• Infusion Rate (mg/kg/hr): The weight-based infusion rate determined by the indication and renal function.
• Total Infusion Rate (mg/hr): The total amount of drug to be infused per hour.
• Final Pump Rate (mL/hr): The calculated rate at which the IV infusion pump should be set to deliver the correct dose continuously.
• Post-PCI Pump Rate (mL/hr): An optional calculation for a reduced infusion rate after a PCI procedure, if selected.

How to Use This Information

To ensure accurate dose calculation, follow these steps corresponding to the calculator's inputs:

1. Select Indication: Choose between PCI / ACS (Percutaneous Coronary Intervention / Acute Coronary Syndrome) or HIT / HITTS (Heparin-Induced Thrombocytopenia).
2. Enter Patient Weight: Input the patient's weight. The tool can accept kilograms (kg) or pounds (lbs) and will convert automatically.
3. Specify Renal Function:
   • Calculate CrCl: Enter the patient's age, serum creatinine (SCr), and biological sex to calculate creatinine clearance using the Cockcroft-Gault formula.
   • Enter Known CrCl: Input a previously determined CrCl value in mL/min.
   • On Hemodialysis: Select if the patient is on hemodialysis, which applies a specific dose adjustment.
4. Set IV Bag Concentration: Select a standard concentration (e.g., 250 mg in 250 mL for 1 mg/mL) or choose Custom to enter the specific milligrams of bivalirudin and total volume in milliliters for your institution's preparation.
5. Indication-Specific Options: Select any relevant options, such as calculating a post-PCI infusion or choosing specific bolus and infusion rates for HIT/HITTS management.

Dosing Overview

PCI/ACS Dosing

The standard dosing regimen for patients undergoing PCI is:

• Bolus: 0.75 mg/kg administered intravenously.
• Infusion: 1.75 mg/kg/hr for the duration of the procedure.

HIT/HITTS Dosing

Dosing is more variable and based on clinical context:

• Bolus: An optional bolus, typically 0.15 to 0.25 mg/kg, may be considered.
• Infusion: A starting infusion rate is typically 0.15 to 0.25 mg/kg/hr, adjusted to achieve the target activated partial thromboplastin time (aPTT).

Renal Impairment Adjustments

Bivalirudin is cleared renally, and dose adjustments are critical:

• Moderate-Severe Impairment (CrCl < 30 mL/min): The infusion rate is typically reduced. For PCI, this is often lowered to 1.0 mg/kg/hr. For HIT, it may be reduced to 0.05 mg/kg/hr. The bolus dose is generally not adjusted.
• Hemodialysis: The infusion rate is significantly reduced. For PCI, it is 0.25 mg/kg/hr, and for HIT, it is 0.025 mg/kg/hr.

Switching Anticoagulants

When switching to or from bivalirudin, careful timing is essential to avoid periods of inadequate or excessive anticoagulation.

• From Unfractionated Heparin (UFH): Bivalirudin can be initiated immediately after discontinuing UFH.
• To Warfarin: If transitioning to long-term anticoagulation, warfarin may be started concurrently with the bivalirudin infusion. Overlap therapy for several days is required until the INR is therapeutic, at which point the bivalirudin can be stopped.
• From a Direct Oral Anticoagulant (DOAC): The initiation of bivalirudin should be timed with the next scheduled dose of the DOAC. Consult specific institutional protocols or guidelines.

Managing Infusion Interruptions

Bivalirudin has a short half-life of approximately 25 minutes in patients with normal renal function. If the continuous infusion is interrupted, its anticoagulant effect will diminish rapidly. The infusion should be resumed as soon as possible at the previously prescribed rate. If the interruption is prolonged, a clinician may consider re-bolusing the patient depending on the clinical scenario and thrombotic risk.

Safety Alerts

• Bleeding Risk: The most common adverse reaction is bleeding. Bivalirudin is contraindicated in patients with active major bleeding. Use with caution in patients with conditions associated with an increased risk of bleeding.
• Acute Stent Thrombosis: Acute stent thrombosis has been reported in patients undergoing PCI who have been treated with bivalirudin. Ensure adequate anticoagulation is maintained throughout and after the procedure.
• Renal Impairment: Dosage adjustments are required for patients with moderate to severe renal impairment (CrCl < 30 mL/min) and those on hemodialysis to prevent drug accumulation and increased bleeding risk.

Frequently Asked Questions

What formula is used to calculate creatinine clearance (CrCl)?

The calculator uses the Cockcroft-Gault formula: CrCl (mL/min) = [(140 - Age) × Weight (kg)] / [72 × SCr (mg/dL)], multiplied by 0.85 for females.

How does the calculator adjust the dose for renal impairment?

For a calculated or known CrCl less than 30 mL/min, or if the patient is on hemodialysis, the calculator automatically reduces the infusion rate according to standard clinical guidelines. The bolus dose for PCI is not typically adjusted.

Can I enter the patient's weight in pounds (lbs)?

Yes, you can select "lbs" from the dropdown menu next to the weight input. The tool will automatically convert the value to kilograms for the calculation.

What should I do if my IV bag concentration is not listed?

Select the "Custom..." option in the IV Bag Concentration dropdown. This will reveal fields where you can enter the total milligrams of bivalirudin and the total volume in milliliters of your IV bag.

Does the calculator provide guidance on post-PCI infusion?

Yes, for the PCI/ACS indication, there is a checkbox to calculate the recommended post-PCI infusion dose, which is typically a reduced rate of 0.25 mg/kg/hr.

Why are the dose options for HIT/HITTS selectable?

Dosing for HIT/HITTS can vary based on institutional protocols, patient-specific factors, and the desired therapeutic target (e.g., aPTT). The options allow clinicians to select the most appropriate starting regimen.

Is the bolus dose for PCI adjusted for poor renal function?

No, according to the prescribing information, the initial 0.75 mg/kg bolus dose for PCI is not adjusted for renal impairment. Only the subsequent infusion rate is modified.

Does this tool replace the need for clinical judgment?

Absolutely not. This tool is for informational and educational purposes only. It is not a substitute for professional medical advice, diagnosis, or treatment. All calculations and doses must be verified by a qualified healthcare professional before administration.

References

• ANGIOMAX (bivalirudin) for Injection - FDA Prescribing Information
• Bivalirudin Injection - DailyMed (National Library of Medicine)
• Warkentin, T. E., Greinacher, A., Koster, A., & Lincoff, A. M. (2008). Treatment and prevention of heparin-induced thrombocytopenia: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). Chest, 133(6 Suppl), 340S–380S. https://doi.org/10.1378/chest.08-0677
• Levine, G. N., et al. (2011). 2011 ACCF/AHA/SCAI Guideline for Percutaneous Coronary Intervention. Journal of the American College of Cardiology, 58(24), e44-e122. https://doi.org/10.1016/j.jacc.2011.08.007